EVLO / Evelo Biosciences' Psoriasis Candidate Shows Reductions In Inflammatory Cytokines

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. more_horizontal

Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical dev more_horizontal

Evelo Biosciences' shares have tumbled 46% in premarket trading after the biotech firm revealed disappointing results in a phase II psoriasis trial fo more_horizontal

Following recent cash raise, EVLO has enough (barely) cash to the next catalyst, phase 2 readout in psoriasis. The event is binary and can make or bre more_horizontal

Evelo Biosciences (NASDAQ: EVLO ) stock is rising higher on Tuesday after the clinical-stage biotechnology company reached a new standstill agreement more_horizontal

Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank # more_horizontal

Evelo Biosciences (NASDAQ: EVLO ) stock is on the rise Thursday after the company said it's shifting focus toward extracellular vesicle (EV) developme more_horizontal

Evelo Biosciences, Inc. (NASDAQ:EVLO ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Shamira Shariffudin - Director more_horizontal